search
Back to results

Exercise to Treat Depression in Individuals With Coronary Heart Disease (UPBEAT)

Primary Purpose

Depression, Heart Diseases

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Supervised Aerobic Exercise
Sertraline
Placebo Pill.
Sponsored by
Duke University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depression focused on measuring Exercise

Eligibility Criteria

35 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Persistent depressive symptoms that may include the following: depressed mood; diminished interest or pleasure in activities; change in appetite; insomnia or hypersomnia; psychomotor agitation or retardation; fatigue or loss of energy; feelings of worthlessness or inappropriate guilt; diminished ability to think or concentrate; or recurrent thoughts of death or suicidal ideations Documented history of coronary heart disease (i.e., a prior heart attack, coronary artery bypass graft, or greater than 75% stenosis in at least one coronary artery) Exclusion Criteria: Experienced an acute heart attack or any revascularization procedure (i.e., CABG or percutaneous transluminal coronary angioplasty) within 60 days of study entry Left ventricular ejection fraction <30% with labile ECG changes prior to testing Currently using a pacemaker Resting blood pressure greater than 160/100 mmHg Left main disease >50% Failure to meet our criteria for depression or achieve a score of ≥9 on the Beck Depression Inventory-II Any other concurrent psychiatric intervention Primary psychiatric diagnosis other than Major or Minor Depressive Episode Primary diagnosis of the following psychiatric disorders: schizophrenia, bipolar disorder, schizoaffective disorder, other psychotic disorder, dementia, current delirium, current obsessive compulsive disorder Experienced psychotic symptoms during the current depressive episode Current abuse or dependence on alcohol or other drugs Acute suicide risk Patients who, during the course of the study, would likely require treatment with additional psychotherapeutic agents Significant medical conditions that would make exercise or sertraline use medically inadvisable (e.g., unstable angina, heart attack within the 3 months prior to study entry, musculoskeletal problems, or congestive heart failure) Abnormal thyroid-stimulating hormone (TSH) level and glucose level greater than or equal to 126 mg/dL Patients who would not be able to be randomized to either the drug (e.g., adverse cardiac events such as prolonged QT interval, allergic responses) or exercise (e.g., musculoskeletal problems, abnormal cardiac response to exercise, such as exercise-induced VT, abnormal blood pressure response, etc.) Currently using medications that would make exercise or sertraline use medically inadvisable (e.g., clonidine, dicumarol, warfarin, anticonvulsants, or MAO inhibitors) Current uncontrolled medical condition that could be causing the depressive symptoms (e.g., thyroid dysfunction, anemia) Pregnant, planning to get pregnant during the study period, or lactating Herbal supplements with purported mood effects (e.g., St. John's wort, valerian, gingko) Current use of antidepressant medication Currently participating in psychotherapy Currently participating in regular aerobic exercise Documented failure to respond to sertraline therapy

Sites / Locations

  • Duke University Medical Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Placebo Comparator

Arm Label

1

2

3

Arm Description

Supervised aerobic exercise, three times per week for 16 weeks.

Sertraline (Zoloft), for 16 weeks.

Placebo control, for 16 weeks.

Outcomes

Primary Outcome Measures

Hamilton Depression Rating Scale
The Hamilton Depression Rating Scale ranges from 0 to 52, with lower scores reflecting lower levels of depression and higher scores greater severity of depression.

Secondary Outcome Measures

Heart Rate Variability (HRV)
HRV is the variation in the time interval between heart beats. ECG was recorded for 24 hours on a 3-channel digital compact ash Holter recorder. During the recording period, patients engaged in their normal patterns of activity. ECG data were downloaded and edited using the Pathfinder digital ambulatory ECG analyzer (DelMar Reynolds, lrvine, California) and HRV was estimated from the standard deviation of all normal R-R intervals (SDNN)
Percent Change in Flow Mediated Dilation (FMD)
Endothelial function assessed by flow mediated dilation (FMD). Brachial artery FMD was assessed following overnight fasting. Longitudinal B-mode ultrasound images of the brachial artery, 4-6 cm proximal to the antecubital crease, were obtained using an Aeuson (Mountain View, California) Aspen ultrasoundplatformwith an 11MHZ linear array transducer. lmages were obtained after 10 min of supine relaxation and during reactive hyperemia, induced following in ation of a forearm pneumatic occlusion cuff to supra-systolic pressure (~200 mmHg) for 5 minutes. FMD was defined as the maximum percent change inarterial diameter relative to restingbaseline from 10-120 sec post-deflation of the occlusion cuff.
C-reactive Protein (CRP)
Platelet Factor 4
Baroreflex Sensitivity (BRS)
Interleuken 6 (IL-6)

Full Information

First Posted
March 9, 2006
Last Updated
June 1, 2015
Sponsor
Duke University
Collaborators
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT00302068
Brief Title
Exercise to Treat Depression in Individuals With Coronary Heart Disease
Acronym
UPBEAT
Official Title
Understanding the Prognostic Benefits of Exercise and Anti-depressant Therapy (UPBEAT)
Study Type
Interventional

2. Study Status

Record Verification Date
May 2015
Overall Recruitment Status
Completed
Study Start Date
July 2006 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
December 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Duke University
Collaborators
Pfizer

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Some individuals with coronary heart disease (CHD) suffer from depression and use antidepressant medications to reduce symptoms. However, preliminary research has shown that exercise may be a more effective way to treat depression in these individuals. The purpose of this study is to evaluate the effects of exercise in reducing depression and improving heart function in individuals with CHD.
Detailed Description
Coronary heart disease (CHD) is caused by a narrowing of the small blood vessels that supply blood and oxygen to the heart. It is the leading cause of death in the United States. Recent evidence has suggested that depression is a significant risk factor for individuals with CHD and may place additional strain on the heart. Selective serotonin reuptake inhibitors (SSRIs), a type of antidepressant medication, have been shown to be especially effective at reducing depression symptoms, particularly for individuals with CHD. However, many people fail to benefit from medication alone or they experience negative side effects. Therefore, a need exists to identify alternative approaches for treating depression in individuals with CHD. Preliminary research has shown that exercise may be an effective way to improve mood and treat depression. More research, however, is needed to confirm the benefits of exercise in individuals with CHD. The purpose of this study is to compare the effectiveness of a supervised exercise program, antidepressant treatment, and placebo in reducing depression and improving heart function in individuals with CHD. This 16-week study will enroll adults with a history of CHD and depression. Participants will be randomly assigned to an aerobic exercise program, antidepressant medication, or placebo. At study entry, standardized psychological questionnaires will be completed and depression levels and exercise tolerance will be assessed. Participants' heart function will be evaluated through measures of flow-mediated vasodilatation, inflammation, platelet function, baroreflex, and heart rate variability. Participants assigned to the exercise program will be required to engage in structured aerobic exercise. Participants assigned to antidepressant medication will receive sertraline, an SSRI or placebo. The treating psychiatrist will be blinded to pill condition and will use supportive measures to help manage medication side effects. Outcome assessors will be unaware of patients' treatment assignments, and only the research pharmacist will be aware of which patients are assigned to sertraline or to placebo. At Week 16, participants will return to the clinic for repeat assessments of baseline measures. A follow-up evaluation will occur six months following the end of treatment, and participants' depression levels and clinical status will be assessed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression, Heart Diseases
Keywords
Exercise

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
101 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Supervised aerobic exercise, three times per week for 16 weeks.
Arm Title
2
Arm Type
Active Comparator
Arm Description
Sertraline (Zoloft), for 16 weeks.
Arm Title
3
Arm Type
Placebo Comparator
Arm Description
Placebo control, for 16 weeks.
Intervention Type
Behavioral
Intervention Name(s)
Supervised Aerobic Exercise
Intervention Description
Supervised aerobic exercise, three times per week, for 16 weeks.
Intervention Type
Drug
Intervention Name(s)
Sertraline
Intervention Description
Sertraline (Zoloft), daily, for 16 weeks.
Intervention Type
Drug
Intervention Name(s)
Placebo Pill.
Intervention Description
Placebo pill, daily, for 16 weeks.
Primary Outcome Measure Information:
Title
Hamilton Depression Rating Scale
Description
The Hamilton Depression Rating Scale ranges from 0 to 52, with lower scores reflecting lower levels of depression and higher scores greater severity of depression.
Time Frame
Measured at 16 weeks
Secondary Outcome Measure Information:
Title
Heart Rate Variability (HRV)
Description
HRV is the variation in the time interval between heart beats. ECG was recorded for 24 hours on a 3-channel digital compact ash Holter recorder. During the recording period, patients engaged in their normal patterns of activity. ECG data were downloaded and edited using the Pathfinder digital ambulatory ECG analyzer (DelMar Reynolds, lrvine, California) and HRV was estimated from the standard deviation of all normal R-R intervals (SDNN)
Time Frame
Baseline, 16 weeks
Title
Percent Change in Flow Mediated Dilation (FMD)
Description
Endothelial function assessed by flow mediated dilation (FMD). Brachial artery FMD was assessed following overnight fasting. Longitudinal B-mode ultrasound images of the brachial artery, 4-6 cm proximal to the antecubital crease, were obtained using an Aeuson (Mountain View, California) Aspen ultrasoundplatformwith an 11MHZ linear array transducer. lmages were obtained after 10 min of supine relaxation and during reactive hyperemia, induced following in ation of a forearm pneumatic occlusion cuff to supra-systolic pressure (~200 mmHg) for 5 minutes. FMD was defined as the maximum percent change inarterial diameter relative to restingbaseline from 10-120 sec post-deflation of the occlusion cuff.
Time Frame
Baseline, 16 weeks
Title
C-reactive Protein (CRP)
Time Frame
Baseline, 16 weeks
Title
Platelet Factor 4
Time Frame
Baseline, 16 weeks
Title
Baroreflex Sensitivity (BRS)
Time Frame
Baseline, 16 weeks
Title
Interleuken 6 (IL-6)
Time Frame
Baseline, 16 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Persistent depressive symptoms that may include the following: depressed mood; diminished interest or pleasure in activities; change in appetite; insomnia or hypersomnia; psychomotor agitation or retardation; fatigue or loss of energy; feelings of worthlessness or inappropriate guilt; diminished ability to think or concentrate; or recurrent thoughts of death or suicidal ideations Documented history of coronary heart disease (i.e., a prior heart attack, coronary artery bypass graft, or greater than 75% stenosis in at least one coronary artery) Exclusion Criteria: Experienced an acute heart attack or any revascularization procedure (i.e., CABG or percutaneous transluminal coronary angioplasty) within 60 days of study entry Left ventricular ejection fraction <30% with labile ECG changes prior to testing Currently using a pacemaker Resting blood pressure greater than 160/100 mmHg Left main disease >50% Failure to meet our criteria for depression or achieve a score of ≥9 on the Beck Depression Inventory-II Any other concurrent psychiatric intervention Primary psychiatric diagnosis other than Major or Minor Depressive Episode Primary diagnosis of the following psychiatric disorders: schizophrenia, bipolar disorder, schizoaffective disorder, other psychotic disorder, dementia, current delirium, current obsessive compulsive disorder Experienced psychotic symptoms during the current depressive episode Current abuse or dependence on alcohol or other drugs Acute suicide risk Patients who, during the course of the study, would likely require treatment with additional psychotherapeutic agents Significant medical conditions that would make exercise or sertraline use medically inadvisable (e.g., unstable angina, heart attack within the 3 months prior to study entry, musculoskeletal problems, or congestive heart failure) Abnormal thyroid-stimulating hormone (TSH) level and glucose level greater than or equal to 126 mg/dL Patients who would not be able to be randomized to either the drug (e.g., adverse cardiac events such as prolonged QT interval, allergic responses) or exercise (e.g., musculoskeletal problems, abnormal cardiac response to exercise, such as exercise-induced VT, abnormal blood pressure response, etc.) Currently using medications that would make exercise or sertraline use medically inadvisable (e.g., clonidine, dicumarol, warfarin, anticonvulsants, or MAO inhibitors) Current uncontrolled medical condition that could be causing the depressive symptoms (e.g., thyroid dysfunction, anemia) Pregnant, planning to get pregnant during the study period, or lactating Herbal supplements with purported mood effects (e.g., St. John's wort, valerian, gingko) Current use of antidepressant medication Currently participating in psychotherapy Currently participating in regular aerobic exercise Documented failure to respond to sertraline therapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James A. Blumenthal, PhD
Organizational Affiliation
Duke University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
11020092
Citation
Babyak M, Blumenthal JA, Herman S, Khatri P, Doraiswamy M, Moore K, Craighead WE, Baldewicz TT, Krishnan KR. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosom Med. 2000 Sep-Oct;62(5):633-8. doi: 10.1097/00006842-200009000-00006.
Results Reference
background
PubMed Identifier
10547175
Citation
Blumenthal JA, Babyak MA, Moore KA, Craighead WE, Herman S, Khatri P, Waugh R, Napolitano MA, Forman LM, Appelbaum M, Doraiswamy PM, Krishnan KR. Effects of exercise training on older patients with major depression. Arch Intern Med. 1999 Oct 25;159(19):2349-56. doi: 10.1001/archinte.159.19.2349.
Results Reference
background
PubMed Identifier
15811982
Citation
Blumenthal JA, Sherwood A, Babyak MA, Watkins LL, Waugh R, Georgiades A, Bacon SL, Hayano J, Coleman RE, Hinderliter A. Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. JAMA. 2005 Apr 6;293(13):1626-34. doi: 10.1001/jama.293.13.1626.
Results Reference
background
PubMed Identifier
15626549
Citation
Dunn AL, Trivedi MH, Kampert JB, Clark CG, Chambliss HO. Exercise treatment for depression: efficacy and dose response. Am J Prev Med. 2005 Jan;28(1):1-8. doi: 10.1016/j.amepre.2004.09.003.
Results Reference
background
PubMed Identifier
12392873
Citation
Dunn AL, Trivedi MH, Kampert JB, Clark CG, Chambliss HO. The DOSE study: a clinical trial to examine efficacy and dose response of exercise as treatment for depression. Control Clin Trials. 2002 Oct;23(5):584-603. doi: 10.1016/s0197-2456(02)00226-x.
Results Reference
background
PubMed Identifier
15184688
Citation
Lett HS, Blumenthal JA, Babyak MA, Sherwood A, Strauman T, Robins C, Newman MF. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med. 2004 May-Jun;66(3):305-15. doi: 10.1097/01.psy.0000126207.43307.c0.
Results Reference
background
PubMed Identifier
22858387
Citation
Blumenthal JA, Sherwood A, Babyak MA, Watkins LL, Smith PJ, Hoffman BM, O'Hayer CV, Mabe S, Johnson J, Doraiswamy PM, Jiang W, Schocken DD, Hinderliter AL. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. J Am Coll Cardiol. 2012 Sep 18;60(12):1053-63. doi: 10.1016/j.jacc.2012.04.040. Epub 2012 Aug 1.
Results Reference
background

Learn more about this trial

Exercise to Treat Depression in Individuals With Coronary Heart Disease

We'll reach out to this number within 24 hrs